© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Thought-provoking interviews with industry experts on topics critical to the diagnosis, treatment, and prevention of progressive eye health
May 13, 2022
The study found that if certain forms of nystagmus that are seen in patients, then there is a higher chance of poor binocular visual function, as well as higher interocular suppression.
May 13, 2022
The study evaluates three separate cases, each which experiences irreversible changes in their corneal structure caused by challenges in getting timely treatment due to various reasons, including insurance, lost to follow up, and the coronavirus pandemic.
May 12, 2022
At ARVO 2022 in Denver, Colorado, Timothy Blenkinsop, MD, presented “3D Eye Organoids with Distinct Cornea.” His presentation outlined how these organoids have developed sophisticated cornea structures.
May 12, 2022
The Phase 3 integrated PEACHTREE and AZALEA study data revealed strong safety and efficacy for triamcinolone acetonide via suprachoirodal injection.
May 11, 2022
The study's primary endpoints were to look at increasing Schirmer's scores, as well as eye discomfort score.
May 11, 2022
Catching up after ASCRS 2022, Ora's Caitlin Black, senior director and therapeutic area head of medical devices, talks about the next generation of ophthalmic device therapies and diagnostics, clinical trial updates and new innovations that are most exciting for presbyopia treatment.
May 11, 2022
Penny Asbell, MD, FACS, MBA, discusses “Antibiotic Resistance among Ocular Staphylococcal Pathogens: Longitudinal Trends in the ARMOR Study."
May 11, 2022
Takeaway: there doesn't seem to be a specific dry eye phenotype that does better or worse.
May 10, 2022
The OpRegen trial is a cell therapy trial, looking to explore potential safety and efficacy for patients with advanced dry age-related macular degeneration (AMD).
May 09, 2022
Diana Do, MD, professor of ophthalmology at Stanford's Byers Eye Institute, presents research on a newly developed, novel patient-reported outcome instrument (PRO) for patients who have proliferative diabetic retinopathy and who are undergoing treatment with either intravitreal anti-VEGF therapy, or panretinal photocoagulation.